SCHEMBL8507659

SCHEMBL8507659

Cc1cc2c(cc1C)Nc1ccccc1C(=O)N2

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK1G1 Q9HCP0 1/20 0.72
▸ ACVR1 Q04771 2/20 0.70
▸ LRRK2 Q5S007 2/20 0.70
▸ PDGFRA P16234 2/20 0.70
▸ FER P16591 2/20 0.70
▸ LTK P29376 1/20 0.70
▸ CDK8 P49336 1/20 0.70
▸ DYRK1B Q9Y463 1/20 0.70
▸ CHEK1 O14757 3/20 0.62
▸ ROS1 P08922 1/20 0.61
▸ CDK5 Q00535 1/20 0.61
▸ MAOA P21397 1/20 0.53
▸ MAOB P27338 1/20 0.53
▸ MEN1 O00255 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ POLB P06746 1/20 0.50
▸ KDR P35968 4/20 0.49
▸ CSF1R P07333 2/20 0.49
▸ RET P07949 2/20 0.49
▸ FGFR1 P11362 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9185276 0.84 CSNK1G1 (1.00) CSNK1G1ACVR1LRRK2PDGFRAFER
SCHEMBL1368292 0.83 LRRK2 (1.00) CSNK1G1ACVR1LRRK2PDGFRAFER
SCHEMBL2420711 0.83 LRRK2 (0.90) CSNK1G1ACVR1LRRK2PDGFRAFER
SCHEMBL366728 0.83 — —
Hydrochloric Acid SCHEMBL6299954 0.81 LRRK2 (0.95) CSNK1G1ACVR1LRRK2PDGFRAFER
SCHEMBL8204226 0.81 CHEK1 (0.72) CSNK1G1ACVR1LRRK2PDGFRAFER
SCHEMBL27980501 0.79 LRRK2 (0.82) CSNK1G1ACVR1LRRK2PDGFRAFER
SCHEMBL9653269 0.78 ACVR1 (0.65) CSNK1G1ACVR1LRRK2PDGFRAFER
SCHEMBL16306322 0.78 ACVR1 (0.65) CSNK1G1ACVR1LRRK2PDGFRAFER
SCHEMBL3408793 0.77 LRRK2 (0.69) CSNK1G1ACVR1LRRK2PDGFRAFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5968478-A DIBENZOTHIEPINE AS NEUROTRANSMITTERS AND FOR DRUG SCREENING AND TREATMENT OF SCHIZOPHRENIA ALLELIX BIOPHARMACEUTICALS, INC. (CA) 1999-10-19 — — US disclosed
Send feedback